- Report
- April 2025
- 193 Pages
Global
From €5225EUR$5,450USD£4,366GBP
- Report
- April 2025
- 398 Pages
Global
From €5369EUR$5,600USD£4,486GBP
- Report
- February 2025
- 200 Pages
Global
From €4304EUR$4,490USD£3,597GBP
- Report
- May 2024
- 136 Pages
Global
From €6230EUR$6,499USD£5,206GBP
- Report
- April 2023
- 175 Pages
Global
From €5655EUR$5,899USD£4,725GBP
- Report
- January 2025
- 82 Pages
India
From €3355EUR$3,500USD£2,804GBP
- Report
- October 2024
- 270 Pages
China
From €3835EUR$4,000USD£3,204GBP
- Report
- June 2023
- 83 Pages
Global
From €3500EUR$3,911USD£3,027GBP
- Report
- October 2024
- 135 Pages
China
From €1726EUR$1,800USD£1,442GBP
Cefalexin is an antibiotic used to treat a variety of bacterial infections, including those caused by Streptococcus, Staphylococcus, and E. coli. It is a member of the cephalosporin class of antibiotics, which are used to treat a wide range of infections, including those caused by Gram-positive and Gram-negative bacteria. Cefalexin is commonly used to treat infections of the respiratory tract, urinary tract, skin, and soft tissue. It is also used to treat some sexually transmitted diseases, such as gonorrhea.
Cefalexin is a widely used antibiotic in the infectious diseases drugs market. It is generally well tolerated and has a low risk of side effects. It is available in both oral and intravenous forms, and is often prescribed as a first-line treatment for bacterial infections.
Some companies in the Cefalexin market include Pfizer, GlaxoSmithKline, Merck, and Sanofi. Show Less Read more